Want to see CAI full AI Analyst Report?
CAI Stock Chart & Stats
$15.52
-$0.13(-0.83%)
At close: 4:00 PM EDT
$15.52
-$0.13(-0.83%)
Day’s Range― - ―
52-Week Range$14.19 - $42.50
Previous CloseN/A
Volume4.93M
Average Volume (3M)3.14M
Market Cap
$6.16B
Enterprise Value$4.70K
Total Cash (Recent Filing)$793.12M
Total Debt (Recent Filing)$452.40M
Price to Earnings (P/E)58.6
Beta2.46
Next Earnings
Nov 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding282,595,180
10 Day Avg. Volume3,669,840
30 Day Avg. Volume3,140,012
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)13.19
Price to Sales (P/S)9.38
P/FCF Ratio113.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$26.29Price Target Upside69.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.11
Revenue Forecast (FY)$1.03B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & GuidanceSustained double-digit organic volume growth and a notably higher full-year revenue target indicate durable demand for profiling services and improving commercial traction. This strengthens recurring clinical testing revenue and supports predictable scale economics for the next several quarters.
Improving Cash GenerationA clear multi-quarter swing to positive operating and free cash flow signals improved core cash conversion and financial flexibility. Positive FCF reduces reliance on external financing, funds capacity expansion and R&D, and makes funding product rollouts and partnerships more sustainable over 2–6 months.
Proprietary Data & AI Competitive MoatA >1.13M-patient clinicogenomic repository plus embedded AI/interpretation tools creates durable differentiation and sticky customer value. Large, longitudinal datasets support biopharma collaborations, product improvement, and higher switching costs versus smaller competitors over the medium term.
Bears Say
Remaining GAAP LossesDespite EBITDA and FCF improvements, large GAAP net losses persist, reflecting non-operational charges and legacy costs. Continued negative net income constrains long-term return metrics, can limit strategic flexibility and investor tolerance, and may pressure earnings quality beyond the near term.
MCED Reimbursement UncertaintyCommercialization of Caris Detect depends on evolving payer and regulatory decisions. Lack of assured coverage creates revenue timing risk and could force prolonged self-pay channels, slowing uptake among broader patient populations and pressuring long-term adoption and revenue durability.
Capacity & Execution RisksRapid product launches and scaling capacity introduce execution risk: lab buildouts, supplier diversification, and sequencing throughput must keep pace to avoid backorders. Operational bottlenecks can raise COGS, delay revenue recognition, and impair margins while expansion proceeds.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $14.19 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $6.16B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 86 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Aug 05, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.006 by -$0.006.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is 0.03.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,595,180 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0 in its last earnings report, missing expectations of $0.006. Following the earnings report the stock price went up 21.581%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.29 (69.37% Upside)
$26.29 (69.37% Upside)
Blogger Sentiment
Bullish
CAI Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 349.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.75%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong operational and financial quarter with substantial year-over-year growth in revenue (+45%), molecular profiling (+55%), and clinical volume (+18%), alongside meaningful margin expansion (GAAP gross margin 68%) and sustained positive adjusted EBITDA and free cash flow. Major product launches (Caris Detect, ChromoSeq, MIClarity V2) and the company’s large proprietary dataset and AI capabilities were highlighted as durable competitive advantages. The primary negatives were operational scaling risks (capacity/backorders), regulatory/reimbursement uncertainty for MCED, MRD evidence-timing uncertainty, and a one-time $25M refinancing charge. Overall, the positives — robust growth, profitability, product launches, and a strong balance sheet — outweigh the manageable execution and timing risks.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$26.29
▲(69.37% Upside)
Technical Analysis
Bio-Techne
―
Veracyte
―
Adaptive Biotechnologies
―
Maravai Lifesciences Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
49.13% Insiders
16.19% Mutual Funds
19.80% Other Institutional Investors
6.92% Public Companies and
Individual Investors